A Novel Mouse Model of Hyperuricemia and Gouty Nephropathy

0
0
0

A Novel Mouse Model of Hyperuricemia and Gouty Nephropathy

Hyperuricemia—the second most common metabolic disease in China after diabetes—affects millions, yet studying its link to kidney damage (a condition called gouty nephropathy) has long been held back by a major barrier: no reliable mouse model that accurately mimics the human disease. Now, researchers from Guangdong Pharmaceutical University, Guangzhou University of Chinese Medicine, and collaborating institutions have developed a solution—a stable, reproducible mouse model that captures the full spectrum of hyperuricemia and its harmful effects on the kidneys.

The Problem: Why Good Mouse Models Matter

Hyperuricemia occurs when serum uric acid levels rise too high, either because the body produces too much uric acid or fails to excrete enough. Over time, this can damage kidney tubules, cause scarring (tubulointerstitial fibrosis), and lead to gouty nephropathy—a painful, progressive form of kidney disease. But without animal models that reliably replicate these processes, scientists struggle to unravel the disease’s mechanisms or test new treatments.

Past attempts to create hyperuricemia models used methods like feeding yeast cream, giving adenine (a purine) alone, or injecting other chemicals. But these often had critical flaws: inconsistent doses, high mouse mortality, or results that were hard to repeat. For example, when the team initially tested 100 mg/kg adenine or 250 mg/kg potassium oxonate (OXO) alone for 7 days, mice only had temporary, low-level uric acid spikes—far from the sustained hyperuricemia seen in humans.

The Study: A New Combo for a Better Model

To fix this, the team tested two combinations of adenine (which boosts uric acid production by adding purines) and potassium oxonate (which blocks uricase—an enzyme that breaks down uric acid in mice, but not in humans). They divided male C57BL/6J mice into three groups:

  • Control: Given a harmless solution (carboxymethyl cellulose sodium, CMC-Na).
  • Ade-100 + OXO-500: 100 mg/kg adenine + 500 mg/kg potassium oxonate.
  • Ade-150 + OXO-300: 150 mg/kg adenine + 300 mg/kg potassium oxonate.

Mice received daily oral doses (gavage) for 3 weeks. The team tracked key markers: serum uric acid (hyperuricemia), serum creatinine (kidney damage), urine output/uric acid, kidney histology (tissue damage), uric acid transporters (URAT1/GLUT9), and inflammatory molecules (TNF-α/IL-1β).

The Results: A Model That Mimics Human Disease

The Ade-100 + OXO-500 group emerged as the clear winner—reproducing the most consistent, severe signs of hyperuricemia and gouty nephropathy:

  1. Hyperuricemia: By week 2, serum uric acid levels were significantly higher than controls, and they stayed elevated through week 3.
  2. Kidney Damage: Serum creatinine (a marker of kidney function) rose by day 7, and kidney tissue showed classic gouty nephropathy signs: dilated tubules, ectatic Bowman spaces (filtering units), needle-like urate crystals, and scarring (fibrosis). This group had worse damage than the Ade-150 + OXO-300 group.
  3. Uric Acid Transport: Two key proteins that reabsorb uric acid in the kidneys—URAT1 and GLUT9—were overexpressed in damaged tubules. This meant more uric acid stayed in the body instead of being excreted, worsening hyperuricemia.
  4. Inflammation: Levels of TNF-α (a pro-inflammatory cytokine) and IL-1β (a driver of gout pain) were much higher than controls, mirroring the inflammation seen in human gout.
  5. Metabolic Stress: Mice in this group ate less, drank more water, and produced more urine—signs of the body struggling with high uric acid and kidney injury.

Why This Model Is a Game-Changer

Compared to older models, this one addresses three major flaws:

  • Stability: Uric acid levels stay high long-term, not just temporarily.
  • Reproducibility: The dose is consistent, so other labs can easily repeat the results.
  • Disease Phenotypes: It captures all key features of human hyperuricemia and gouty nephropathy—not just high uric acid, but kidney damage, altered uric acid transport, and inflammation.

What This Means for Research

This model fills a critical gap in hyperuricemia research. Scientists can now use it to:

  • Study how hyperuricemia damages kidneys at the molecular level.
  • Test new drugs that lower uric acid or protect the kidneys.
  • Explore why some people with hyperuricemia develop gouty nephropathy while others don’t.

Conclusion

The team’s work—published in the Chinese Medical Journal—provides a much-needed tool to accelerate progress against hyperuricemia and gouty nephropathy. By combining adenine and potassium oxonate in the right doses, they’ve created a mouse model that’s more stable, reproducible, and true to the human disease than ever before. For millions living with hyperuricemia, this could be a step closer to better treatments—and maybe even cures.

Guan J, Huang XQ, Dong JL, Lu HM, Lin YW, Liu M, Yi ZB, Wu LM, Huang YM, Lan T. A novel mouse model of hyperuricemia and gouty nephropathy. Chin Med J 2020;133:2012–2014. doi:10.1097/CM9.0000000000000964

Was this helpful?

0 / 0